Biothera Pharmaceuticals

Biothera Pharmaceuticals was a clinical-stage biotechnology company dedicated to developing innate immune modulators for the treatment of cancer. The company's lead candidate, Imprime PGG, is a systemic biological product derived from yeast that functions as a pathogen-associated molecular pattern (PAMP). By binding to complement receptors on innate immune cells, Imprime PGG was designed to enhance the anti-tumor activity of both monoclonal antibodies and checkpoint inhibitors. The company's clinical pipeline focused on Phase 2 trials for indications such as non-small cell lung cancer, metastatic melanoma, and colorectal cancer. Biothera's approach aimed to bridge the gap between innate and adaptive immunity to overcome tumor resistance. In 2020, the company was acquired by HiberCell, which integrated the Imprime PGG program into its portfolio of therapies targeting cancer dormancy and relapse.